{
    "nct_id": "NCT05795595",
    "official_title": "A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors",
    "inclusion_criteria": "1. Age â‰¥18 years.\n2. Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma.\n3. Eastern Cooperative Oncology Group performance status 0 or 1.\n4. Adequate renal, liver, cardiac and pulmonary organ function.\n5. Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX131 infusion.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior treatment with anti-CD70 targeting agents\n2. History of certain central nervous system (CNS), cardiac or pulmonary conditions.\n3. Presence of uncontrolled bacterial, viral, or fungal infection.\n4. Active HIV, hepatitis B virus or hepatitis C virus infection.\n5. Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.\n6. Women who are pregnant or breastfeeding.",
    "miscellaneous_criteria": "Key"
}